May 14, 2021
aTyr Pharma Announces First Quarter 2021 Results and Provides Corporate Update
Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quarter. Preclinical data for IND…
Pharmaceuticals, Biotechnology and Life Sciences
Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quarter. Preclinical data for IND…
4D-150 designed as an intravitreal gene therapy with dual transgenes expressing aflibercept and VEGF-C RNAi for the treatment of wet…
Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up C-144-01 Study Contributes to Advancement in…
BRIDGEWATER, N.J., May 12, 2021 (GLOBE NEWSWIRE) — Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated…
LOS ANGELES, May 12, 2021 (GLOBE NEWSWIRE) — Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies…
– Marks next step to bring the potential first ever hormone replacement therapy for hypoparathyroidism to Japan –COPENHAGEN, Denmark, May…
Durable, therapeutically relevant levels of anti-SARS-CoV-2 spike antibodies produced from the liver in a mouse model Next-generation rapid enzymatic synthesis…
– PP-001: proof-of-concept study in Austria for dry eye patients expected to initiate in Q3:21; U.S. IND submission planned in…
MINNEAPOLIS, May 12, 2021 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics…
ANN ARBOR, Mich, May 12, 2021 (GLOBE NEWSWIRE) — Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or “Company”), a veterinary health company creating…